Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_2
1
20%
Ph phase_4
3
60%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 43 (60.0%)
N/A1 (20.0%)

Trials by Status

completed240%
unknown120%
withdrawn240%

Recent Activity

0 active trials
Showing 5 of 5
withdrawnphase_2

A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema

NCT04588948
unknownphase_4

Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept

NCT03056079
completedphase_4

Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy

NCT02495181
withdrawnphase_4

Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

NCT03059277
completednot_applicable

Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment

NCT02381730

Clinical Trials (5)

Showing 5 of 5 trials
NCT04588948Phase 2

A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema

Withdrawn
NCT03056079Phase 4

Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept

Unknown
NCT02495181Phase 4

Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy

Completed
NCT03059277Phase 4

Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

Withdrawn
NCT02381730Not Applicable

Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5